Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
TNFRSF11B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 11B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF11B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GPR31 Biologics Sequence Review Report 2026: 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR31 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
TNFRSF10A Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10A Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF10A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
TLR2 Biologics Sequence Review Report 2026: Toll-like receptor 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TLR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TLR5 Biologics Sequence Review Report 2026: Toll-like receptor 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TLR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB1BP1 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB1BP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CXCL13 Biologics Sequence Review Report 2026: C-X-C motif chemokine 13 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF17 Biologics Sequence Review Report 2026: Fibroblast growth factor 17 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
VEGFD Biologics Sequence Review Report 2026: Vascular endothelial growth factor D Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of VEGFD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF16 Biologics Sequence Review Report 2026: Fibroblast growth factor 16 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF10 Biologics Sequence Review Report 2026: Fibroblast growth factor 10 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCL16 Biologics Sequence Review Report 2026: C-C motif chemokine 16 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
164
165
166
167
168
>>
1470
>